Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001641172-25-016520
Filing Date
2025-06-25
Accepted
2025-06-25 17:22:13
Documents
17

Document Format Files

Seq Description Document Type Size
1 DEFA14A formdefa14a.htm   iXBRL DEFA14A 806063
2 GRAPHIC formdef14a_001.jpg GRAPHIC 43678
3 GRAPHIC formdef14a_002.jpg GRAPHIC 46990
  Complete submission text file 0001641172-25-016520.txt   1612678

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE cycc-20241231.xsd EX-101.SCH 4664
5 XBRL DEFINITION FILE cycc-20241231_def.xml EX-101.DEF 8434
6 XBRL LABEL FILE cycc-20241231_lab.xml EX-101.LAB 59504
7 XBRL PRESENTATION FILE cycc-20241231_pre.xml EX-101.PRE 43154
19 EXTRACTED XBRL INSTANCE DOCUMENT formdefa14a_htm.xml XML 114468
Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-50626 | Film No.: 251074555
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)